Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Logos Global Management LP acquired a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 539,079 shares of the company’s stock, valued at approximately $6,722,000. Logos Global Management LP owned 52.14% of Avalo Therapeutics at the end of the most recent reporting period.

Separately, Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $9.67 on Tuesday. Avalo Therapeutics, Inc. has a 1 year low of $3.95 and a 1 year high of $52.75. The firm has a 50-day moving average of $9.88 and a 200 day moving average of $11.15.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, August 12th. The company reported ($14.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 306.52%. On average, equities analysts forecast that Avalo Therapeutics, Inc. will post -7.78 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.